http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
비글개에서 인체 재조합 적혈구 조혈인자, rHu-EPO의 급성독성에 관한 연구
조명행,성하정,김형식,곽승준,천선아,임소영,김원배,김병문,안병옥,이병무,Cho, Myung-Hang,Seong, Ha-Jung,Kim, Hyung-Sik,Kwack, Seung-Jun,Chun, Sun-Ah,Lim, So-Young,Kim, Won-Bae,Kim, Byoung-Moon,Ahn, Byoung-Ok,Lee, Byung-Mu 한국독성학회 1996 Toxicological Research Vol.12 No.2
The acute toxicity of rHu-EPO, newly developed recombinant erythropoietin, was tested in beagle dogs. rHu-EPO, when administered intravenously at 25, 000 IU/kg, did not cause any death. Also, rHu-EPO did not induce any change of body weight, food intake and clinical signs compared to controls. There were no significant changes in hematological, urine analysis and pathological examination. These results showed that rHu-EPO did not induce any remarkable toxic response and the $LD_50$ was greater than 25, 000 IU/kg in beagle dogs.
비글개에서 인체 재조합 적혈구 조혈인자 , rHuEPO 의 아만성 정맥독성에 관한 연구
조명행(Myung Haing Cho),성하정(Ha Jung Seong),김형식(Hyung Sik Kim),곽승준(Seung Jun Kwack),천선아(Sun Ah Chun),한하수(Ha Su Han),임소영(So Young Lim),안미영(Mi Young Ahn),김원배(Won Bae Kim),김병문(Byoung Moon Kim),안병옥(Byoung Ok 한국응용약물학회 1998 Biomolecules & Therapeutics(구 응용약물학회지) Vol.6 No.3
The subchronic toxicity study of rHuEPO, a newly developed recombinant erythropoietin, was investigated for 13 weeks in Beagle dogs intravenously treated with doses of 100, 500 and 2,500 IU/㎏/day. There were no significant changes in body weight, food intake, physical and opthalmic examination, urine analysis, etc. Any toxic response was not observed except for enlarged spleen and extramedullary hematopoiesis. These results indicate that the no-observed adverse effect level (NOAEL) of rHuEPO is 100 IU/㎏ in Beagle dogs.
호중구 감소증을 유도한 마우스에서의 유전자 재조합 인과립구 콜로니자극인자의 효과
조명행(Myung Haing Cho),유아선(Ah Sun Yu),방명주(Ming Zhu Fang),곽형일(Hyung Il Kwak),성하정(Ha Jung Seong),강관엽(Koan Yeob Kang),최승진(Seung Jin Choi),정경환(Kyung Hwan Jung),박두홍(Doo Hong Park),안길환(Gil Hwan Ahn) 한국응용약물학회 1998 Biomolecules & Therapeutics(구 응용약물학회지) Vol.6 No.2
Administration of 3 type KGCs [recombinant human granulocyte colony-stimulating factor (rhGCSF)] to mice with cyclophosphamide (CPA)-induced neutropenia for 4 consecutive days from the day after the CPA dosing (100 mg/kg) resulted in a dose dependent increase in the peripheral blood neutrophil count 6 hours after the final KGC injection. Within the KGC dose range of 0.1 to 40 ㎍ per mouse per day, there was a sigmoidal relationship between the logarithm of the dose and the peripheral blood neutrophil count (relative value for neutrophil count of the basal dose) in the treated mice. The sigmoidal relationship of test KGC preparations shows that there is a saturation point in terms of efficacy. Compared with effect of KGC-Orange, Green, and Blue, KGC-Orange recovers neutrophils more effectively than the others do.
비글개에서 인체 재조합 적혈구 조혈인자 , rHu-EPO 의 아급성정맥독성시험
조명행(Myung Hang Cho),성하정(Ha Jung Seong),김형식(Hyung Sik Kim),곽승준(Seung Jun Kwack),임소영(So Young Lim),천선아(Sun Ah Chun),김원배(Won Bae Kim),김병문(Byoung Moon Kim),안병옥(Byoung Ok Ahn),이병무(Byung Mu Lee) 한국응용약물학회 1996 Biomolecules & Therapeutics(구 응용약물학회지) Vol.4 No.4
The subacute toxicity was investigated in Sprague-Dawley rats orally treated with KDRD-010 at the doses of 0.056, 0.28, and 1.4 g/㎏ for one month. There were no clinical signs and pathological changes compared with control group. Body weights were not significantly changed between control and treatment groups. In hematological and biochemical serum parameters, all mean values appear to be within the normal range. In pathological examinations, hemorrhages of lung was observed in one male rat at low dose group and one female rat at high dose group of KDRD-010, but it was not considered to be caused by KDRD-010. These results suggest that KDRD-010 dose not induce any significant subacute oral toxicities in Sprague-Dawley rats.
우나리야(Na Ri Yah Woo),김태수(Tae Su Kim),박희운(Hee Woon Park),박춘근(Chun Geon Park),성하정(Ha Jeong Seong),고상범(Sang Beom Ko),정진우(Jin Woo Jung),강명화(Myung Hwa Kang) 한국식품영양과학회 2005 한국식품영양과학회지 Vol.34 No.9
활나물의 항산화 효과를 측정하기 위하여 잎, 줄기, 뿌리 및 종자의 부위별로 분리하여 methylen chloride와 ethanol 혼합용매에 의해 추출하였다. 활나물의 부위로 추출수율은 줄기 4.47%, 잎 3.95%, 종자 2.90%, 뿌리 2.67%의 순으로 줄기 부분의 추출수율이 가장 높았다. 총 페놀성 화합물 함량은 잎 2.98, 뿌리 2.34, 종자 2.26, 줄기 2.11 ㎎/mL로 잎추출물에서 가장 높았다. SOD 유사활성은 잎 추출물의 활성이 86.27%로 가장 높았으며, 줄기와 뿌리 추출물은 각각 56.32, 50.29%이었으며, 종자 추출물은 경우 16.82%로 가장 낮았다. 잎, 줄기, 뿌리 추출물의 SOD 유사활성은 천연항산화제인 tocopherol보다 매우 높았다. 활나물 부위별 추출물의 전자공여능은 잎과 줄기 추출물에서 각각 16.87, 16.06%로 매우 높았으며, 뿌리 추출물과 종자 추출물이 각각 11.13, 9.31%로 tocopherol 9.28%보다 높았다. 활나물 부위별 추출물에 대한 hydroxy radical 소거활성은 잎 추출물에서 42.90%로 가장 높게 나타났고, 줄기, 종자, 뿌리 추출물은 각각 41.03, 37.80, 37.62%이었으며, 천연항산화제인 tocopherol 32.38%이 가장 낮은 결과를 보여주었다. 종자 추출물의 hydrogen radical 소거능이 53.51%로 가장 높게 나타났으며, tocopherol의 53.81%와 비슷한 활성 수준을 보여 주었다. 따라서 활나물 부위별 추출물의 항산화 효과를 측정한 결과 잎 추출물이 가장 항산화 활성이 높았으며, 활나물은 천연항산화제로의 개발 가능성이 있음을 확인할 수 있었다. This study was carried to develop the new functional food material by exploring natural antioxidant substances of Crotalaria sessiflora L. We compared antioxidative activity of potential antioxidant substances extracted from Crotalaria sessiflora L. The order of extract yield of Crotalaria sessiflora L. were stem>leaves> seed>root. Antioxidative activities of Crotalaria sessiflora L. were measured by total polyphenol contents, EDA (electron donating activity), SOD (superoxide dismutase)-like activity, hydroxyl radical scavenging ability and hydrogen peroxide radical scavenging ability. Total polyphenol acid content was much higher in leaves Ex than other extracts. And leaves Ex showed the most excellent antioxidative activity (86.27%) in terms of SOD-like activity. The EDA was ordered leaves Ex>stem Ex>seed Ex>root Ex. Hydroxy radical scavenging ability was the most effective in leaves Ex, and hydorogen peroxide radical scavenging ability was the highest in seed Ex. Therefore we could be certain that leaves Ex was the most effective in antioxidative activity from Crotalaria sessiflora L.
비글개에서 인체 재조합 적혈구 조혈인자, rHuEPO의 아만성 정맥독성에 관한 연구
조명행,성하정,김형식,곽승준,천선아,한하수,임소영,안미영,김원배,김병문,안병옥,홍성렬,이병무 성균관대학교 약학연구소 1998 成均藥硏論文集 Vol.10 No.1
The subchronic toxicity study of rHuEPO, a newly developed recombinant erythropoietin, was investigated for 13 weeks in Beagle dogs intravenously treated with doses of 100,500 and 2,500 IU/㎏/day. There were no significant changes in body weight, food intake, physical and opthalmic examination, urine analysis, etc. Any toxic response was not observed except for enlarged spleen and extramedullary hematopoiesis. These results indicate that the no-observed adverse effect level (NOAEL) of rHuEPO is 100 IU/㎏ in Beagle dogs.